Mesoblast Limited vs Tripadvisor Inc Common Stock — how do they compare? Mesoblast Limited trades at $16.9 (market cap $2.21B), while Tripadvisor Inc Common Stock trades at $10.52 (market cap $1.28B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| MESO | TRIP | |
|---|---|---|
Market Cap | $2.21B | $1.28B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $19.14 |
52-Week Low | $12.88 | $9.24 |
Enterprise Value | $2.21B | $1.33B |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Tripadvisor (TRIP) trades at $10.78, flat on the day, with a bearish technical signal but bullish oscillators. The company reported Q2 2026 EPS of $0.35, missing estimates, though revenue reached $1.89B in 2025 with a net income margin of 2.11%. Recent news highlights competitive pressures from AI travel tools and the pending $700M sale of TheFork to American Express, providing a cash infusion.
Outlook remains mixed; the stock is undervalued on P/S (0.72) but carries a high P/E (127.18). Risks include stiff competition and earnings misses, yet analyst consensus targets $13.29, suggesting 23% upside. Investor sentiment is cautious, with 62.5% hold ratings, but Viator's U.S. leadership offers a growth avenue amid challenges.
Trailing returns across standard periods
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →